Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesCancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Askling J et al. – The goal of this study was to determine the short-term and medium-term risks of cancer in patients receiving anti-tumor necrosis factor (anti-TNF) therapies that have proven effective in the treatment of chronic inflammatory conditions. During the first 6 years after the start of anti-TNF therapy in routine care, no overall elevation of cancer risk and no increase with followup time were observed.
Methods- Identified and analyzed for cancer occurrence a national cohort of 6,366 patients with RA who first started anti-TNF therapy between January 1999 and July 2006
- Used national biologics-naive RA cohort (n = 61,160), a cohort of RA patients newly starting methotrexate (n = 5,989), a cohort of RA patients newly starting disease-modifying antirheumatic drug combination therapy (n = 1,838), and general population
- RRs estimated using Cox regression analyses, examining overall RR as well as RR by time since first start of anti-TNF therapy, by duration of active anti-TNF therapy, and by anti-TNF agent received
- During 25,693 person-years of followup in 6,366 patients newly starting anti-TNF, 240 first cancers occurred, yielding an RR of 1.00 (95% confidence interval 0.86-1.15) versus biologics-naive RA cohort, and similar RRs versus other 2 RA comparators
- RRs did not increase with increasing time since the start of anti-TNF therapy, nor with cumulative duration of active anti-TNF therapy
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of biomagnetic therapy versus physiotherapy for treatment of knee osteoarthritis: A randomized controlled trial
Journal of Rehabilitation Medicine, 11/20/09
Prediction of vertebral fractures is specific for gender and site of bone mineral density measurement
Journal of Rheumatology, 11/20/09
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis
Journal of Rheumatology, 11/20/09
Sponsor
Article Search
Sponsor
Sponsor